Edition:
India

Tandem Diabetes Care Inc (TNDM.OQ)

TNDM.OQ on NASDAQ Stock Exchange Global Market

2.93USD
22 Jan 2018
Change (% chg)

$0.02 (+0.69%)
Prev Close
$2.91
Open
$2.95
Day's High
$3.11
Day's Low
$2.85
Volume
137,626
Avg. Vol
110,490
52-wk High
$30.00
52-wk Low
$2.15

Select another date:

Wed, Jan 10 2018

BRIEF-Tandem Diabetes Care Sees Q4 2017 GAAP Sales Of About $39 Mln to $40 Mln

* TANDEM DIABETES CARE ANNOUNCES PRELIMINARY 2017 RESULTS AND PROVIDES 2018 GUIDANCE

BRIEF-Tandem Diabetes Care Says May Offer Combination Of Stock Not Exceeding $10.7 Mln

* TANDEM DIABETES CARE SAYS MAY OFFER COMBINATION OF STOCK, PREFERRED STOCK, WARRANTS OR UNITS HAVING INITIAL OFFERING PRICE NOT EXCEEDING $10.7 MILLION Source text: (http://bit.ly/2oGBPwa) Further company coverage:

BRIEF-Tandem Diabetes Care reports Q3 sales of $27 million

* Tandem Diabetes Care reports third quarter 2017 financial results

BRIEF-‍Tandem Diabetes Care to provide all t:slim X2 insulin pump features approved in 2018 to users at no cost

* ‍Tandem Diabetes Care to provide all t:slim x2 insulin pump features approved in 2018 to users at no cost, expands existing dexcom welcome offer for animas customers​

BRIEF-Empery Asset Management reports 5.63 pct passive stake in Tandem Diabetes Care

* Empery Asset Management Lp reports 5.63 pct passive stake in Tandem Diabetes Care Inc as of Oct 13 - SEC filing‍​ Source text: (http://bit.ly/2hSFBfg) Further company coverage:

BRIEF-Tandem Diabetes Care sees Q3 sales of about $26.5 mln to $27.5 mln

* Sees Q3 sales about $26.5 million to $27.5 million - sec filing

BRIEF-Tandem Diabetes Care announces proposed public offering of common stock

* Tandem Diabetes Care announces proposed underwritten public offering of common stock, Series A warrants and Series B warrants Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care‍ shareholders approv reverse stock split

* Tandem Diabetes Care Inc- ‍ shareholders subsequently approved reverse stock split at a ratio of 1-for-10​ Source text for Eikon: Further company coverage:

BRIEF-Tandem Diabetes Care announces FDA approval, launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

* Tandem Diabetes care announces FDA approval and launch of t:slim X2 insulin pump with Dexcom G5 mobile CGM integration

BRIEF-Tandem Diabetes Care announces issuance of patent related to remote bolus feature for medical infusion pumps

* Tandem Diabetes Care announces issuance of patent related to remote bolus feature for medical infusion pumps Source text for Eikon: Further company coverage:

Select another date: